Elanco Animal Health Incorporated (ELAN)
| Market Cap | 10.99B |
| Revenue (ttm) | 4.48B |
| Net Income (ttm) | 434.00M |
| Shares Out | 496.81M |
| EPS (ttm) | 0.88 |
| PE Ratio | 25.27 |
| Forward PE | 23.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,238,740 |
| Open | 22.16 |
| Previous Close | 22.27 |
| Day's Range | 21.80 - 22.27 |
| 52-Week Range | 8.02 - 22.45 |
| Beta | 1.65 |
| Analysts | Buy |
| Price Target | 20.00 (-9.58%) |
| Earnings Date | Nov 5, 2025 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price target is $20.0, which is a decrease of -9.58% from the latest price.
News
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tic...
Elanco gets US FDA emergency nod for dog drug as threat of flesh-eating parasite looms
Elanco Animal Health said on Friday it had received an emergency use authorization from the U.S. Food and Drug Administration for its flea and tick drug to treat dogs infected with a flesh-eating para...
Elanco Animal Health Obtains FDA Authorization for Screwworm Treatment
Health and Human Services Secretary Robert F. Kennedy Jr. determined that New World screwworm presents significant potential for a public health emergency.
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First FDA emergency use authorization (EUA) ever granted f...
Elanco to Host Investor Day on December 9
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m.
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025.
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
FDA now concludes "t he totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i Further evaluation of supplemental scie...
Elanco Animal Health Incorporated (ELAN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Elanco Animal Health Incorporated (NYSE:ELAN) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Jeffrey Simmons - President, CEO & Director Ro...
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval Cred...
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind. , Aug. 27, 20...
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookli...
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.
Elanco Animal Health Incorporated (ELAN) Q2 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.
Elanco Animal Health Q2: Rising Innovation Revenue, Initiate At Buy
I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and st...
Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook
Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.
Elanco Animal Health Reports Second Quarter 2025 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% or...
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market ...
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.
Elanco's dog flu vaccine gets USDA nod
Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which offers dogs protection against serious respiratory disease.
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike cu...
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providi...
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.
Elanco Releases 2024 Impact Report and Introduces New Framework
GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, n...
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today th...
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itch...